REFERENCES
1. Merola JF, Li T, Li WQ, et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41:486-489.
2. American Academy of Dermatology. 10 reasons why your scalp itches and how to get relief. Available at: https://www.aad.org/public/everyday-care/ itchy-skin/itch-relief/relieve-scalp-itch. Accessed: 17-Dec-2020.
3. Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31:1686-1692.
4. Dennehy EB, Zhang L, Amato D, et al. Ixekizumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: Results from UNCOVER 3. J Drugs Dermatol. 2016;15:958-961.
5. Dogra A, Arora AK. Nail psoriasis: the journey so far. Indian J Dermatol. 2014;59:319-333.
6. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-1072.
7. van de Kerkhof P, Guenther L, Gottlieb AB, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31:477-482.
8. Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017;28:282-287.
9. Paul C, Reich K, Gottlieb AB, et al; CAIN457A2211 study group. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimenfinding phase 2 trial. J Eur Acad Dermatol Venereol. 2014;28:1670-1675.
10. Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderateto- severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77:667-674.
11. Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76:70-80.
12. Reich K, Blauvelt A, Armstrong A, et al. Secukinumab, a fully human antiinterleukin- 17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;176:752-758.
13. Blauvelt A, Lebwohl MG, Mabuchi T, et al. Long-term efficacy and safety of ixekizumab: 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol (2020). https://doi.org/10.1016/j.jaad.2020.11.022
14. Leonardi CL, Blauvelt A, Sofen HL, et al. Rapid improvements in healthrelated quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31:1483-1490.
15. Gordon KB, Blauvelt A, Papp KA, et al; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345-356.
16. Leonardi C, Reich K, Foley P, et al. Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials. Dermatol Ther (Heidelb). 2020;10:431-447.
17. Langley RG, Rich P, Menter A, et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2015;29:1763-1770.
18. van de Kerkhof P, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol. 2001;2:159-165.
19. Pasch MC. Nail psoriasis: a review of treatment options. Drugs. 2016;76:675-705.
20. Wasel N, Tha i D, French LE, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S). Dermatol Ther (Heidelb). 2020;10:663-670.
21. Chung J, Duffin KC, Takeshita J, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014;71:623-632.
22. Pinter A, Wilsmann-Theis D, Peitsch WK, M ssner R. Interleukin-17 receptor A blockade with brodalumab in palmoplantar psoriasis: report on four cases. J Dermatol. 2019;46:426-430.
23. Elewski R, Yamauchi P, Green L, et al.. Improvement in nail psoriasis with brodalumab over 52 weeks: an analysis of two phase 3 studies. J Am Acad Dermatol. 2018;79(3 Suppl 1):abstract 162. DOI:https://doi.org/10.1016/j. jaad.2018.05.665
24. Langley RG, Kimball AB, Nak H, et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J Eur Acad Dermatol Venereol. 2019;33:333-339.
25. Langley RG, Saurat JH, Reich K; Nail Psoriasis Delphi Expert Panel. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. J Eur Acad Dermatol Venereol. 2012;26:373-381.
2. American Academy of Dermatology. 10 reasons why your scalp itches and how to get relief. Available at: https://www.aad.org/public/everyday-care/ itchy-skin/itch-relief/relieve-scalp-itch. Accessed: 17-Dec-2020.
3. Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31:1686-1692.
4. Dennehy EB, Zhang L, Amato D, et al. Ixekizumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: Results from UNCOVER 3. J Drugs Dermatol. 2016;15:958-961.
5. Dogra A, Arora AK. Nail psoriasis: the journey so far. Indian J Dermatol. 2014;59:319-333.
6. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-1072.
7. van de Kerkhof P, Guenther L, Gottlieb AB, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31:477-482.
8. Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017;28:282-287.
9. Paul C, Reich K, Gottlieb AB, et al; CAIN457A2211 study group. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimenfinding phase 2 trial. J Eur Acad Dermatol Venereol. 2014;28:1670-1675.
10. Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderateto- severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77:667-674.
11. Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76:70-80.
12. Reich K, Blauvelt A, Armstrong A, et al. Secukinumab, a fully human antiinterleukin- 17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;176:752-758.
13. Blauvelt A, Lebwohl MG, Mabuchi T, et al. Long-term efficacy and safety of ixekizumab: 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol (2020). https://doi.org/10.1016/j.jaad.2020.11.022
14. Leonardi CL, Blauvelt A, Sofen HL, et al. Rapid improvements in healthrelated quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31:1483-1490.
15. Gordon KB, Blauvelt A, Papp KA, et al; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345-356.
16. Leonardi C, Reich K, Foley P, et al. Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials. Dermatol Ther (Heidelb). 2020;10:431-447.
17. Langley RG, Rich P, Menter A, et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2015;29:1763-1770.
18. van de Kerkhof P, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol. 2001;2:159-165.
19. Pasch MC. Nail psoriasis: a review of treatment options. Drugs. 2016;76:675-705.
20. Wasel N, Tha i D, French LE, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S). Dermatol Ther (Heidelb). 2020;10:663-670.
21. Chung J, Duffin KC, Takeshita J, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014;71:623-632.
22. Pinter A, Wilsmann-Theis D, Peitsch WK, M ssner R. Interleukin-17 receptor A blockade with brodalumab in palmoplantar psoriasis: report on four cases. J Dermatol. 2019;46:426-430.
23. Elewski R, Yamauchi P, Green L, et al.. Improvement in nail psoriasis with brodalumab over 52 weeks: an analysis of two phase 3 studies. J Am Acad Dermatol. 2018;79(3 Suppl 1):abstract 162. DOI:https://doi.org/10.1016/j. jaad.2018.05.665
24. Langley RG, Kimball AB, Nak H, et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J Eur Acad Dermatol Venereol. 2019;33:333-339.
25. Langley RG, Saurat JH, Reich K; Nail Psoriasis Delphi Expert Panel. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. J Eur Acad Dermatol Venereol. 2012;26:373-381.
AUTHOR CORRESPONDENCE
Kim A. Papp MD PhD FRCPC kapapp@probitymedical.com
